CytomX Therapeutics, Inc. (CTMX)
NASDAQ: CTMX · Real-Time Price · USD
3.360
+0.040 (1.20%)
Aug 5, 2026, 10:22 AM EDT - Market open
CytomX Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 35.54 | 76.2 | 138.1 | 101.21 | 53.16 | 37.31 | |
Revenue Growth | -75.91% | -44.82% | 36.45% | 90.38% | 42.48% | -45.47% |
Gross Profit | 35.54 | 76.2 | 138.1 | 101.21 | 53.16 | 37.31 |
Selling, General & Admin | 31.1 | 29.84 | 29.73 | 30.02 | 42.85 | 39.16 |
Research & Development | 69.1 | 68.73 | 83.38 | 77.68 | 111.65 | 114.19 |
Total Operating Expenses | 100.2 | 98.57 | 113.11 | 107.7 | 154.5 | 153.35 |
Operating Income | -64.66 | -22.36 | 25 | -6.48 | -101.34 | -116.04 |
Interest Income | 5.74 | 5.21 | 7.14 | 9.84 | 1.68 | 0.26 |
Other Non-Operating Income (Expense) | 0.01 | 0.03 | -0.04 | -0.03 | 0.34 | -0.08 |
Total Non-Operating Income (Expense) | 5.75 | 5.23 | 7.1 | 9.81 | 2.02 | 0.17 |
Pretax Income | -58.91 | -17.13 | 32.09 | 3.32 | -99.32 | -115.87 |
Provision for Income Taxes | 0.23 | 0.24 | 0.22 | 3.89 | - | - |
Net Income | -40.89 | -17.37 | 31.87 | -0.57 | -99.32 | -115.87 |
Net Income Attributable to Preferred Dividends | - | 3 | - | - | - | - |
Net Income to Common | -40.89 | -20.37 | 31.87 | -0.57 | -99.32 | -115.87 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 160 | 138 | 84 | 74 | 66 | 64 |
Shares Outstanding (Diluted) | 160 | 138 | 85 | 74 | 66 | 64 |
Shares Change | 86.93% | 62.77% | 14.82% | 12.27% | 2.48% | 39.01% |
EPS (Basic) | -0.41 | -0.15 | 0.38 | -0.01 | -1.51 | -1.81 |
EPS (Diluted) | -0.41 | -0.15 | 0.38 | -0.01 | -1.51 | -1.81 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | -80.19 | -75.81 | -86.54 | -56.88 | -112.53 | -120.64 |
Free Cash Flow Growth | - | - | - | - | - | - |
Free Cash Flow Per Share | -0.50 | -0.55 | -1.02 | -0.77 | -1.71 | -1.88 |
Gross Margin | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
Operating Margin | -181.92% | -29.35% | 18.10% | -6.41% | -190.61% | -311.00% |
Profit Margin | -115.05% | -22.79% | 23.08% | -0.56% | -186.82% | -310.54% |
FCF Margin | -225.63% | -99.48% | -62.66% | -56.19% | -211.67% | -323.33% |
EBITDA | -63.42 | -20.99 | 26.76 | -4.31 | -98.89 | -113.34 |
EBITDA Margin | -178.43% | -27.54% | 19.38% | -4.26% | -186.02% | -303.75% |
EBIT | -64.66 | -22.36 | 25 | -6.48 | -101.34 | -116.04 |
EBIT Margin | -181.92% | -29.35% | 18.10% | -6.41% | -190.61% | -311.00% |
Effective Tax Rate | -0.40% | -1.39% | 0.70% | 117.12% | 0.00% | 0.00% |